{"entity":{"type":"insider","cik":"0001798550","url":"/insider/0001798550","json_url":"/insider/0001798550.json","name":"Sumitomo Chemical Co., Ltd.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":94,"n_filings":44,"first":"2020-02-21","last":"2023-06-26","span_basis":"filed_date"},"name_variants":[{"name":"Sumitomo Chemical Co., Ltd.","source":"filing","n_filings":44,"first_seen":"2020-02-21","last_seen":"2023-06-26"}],"transactions":[{"id":8644795,"accession":"0000899243-23-016487","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-016487","line_url":"/filing/0000899243-23-016487#line-1","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Roivant Sciences Ltd.","issuer_ticker":"ROIV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitomo Pharma Co., Ltd.; Sumitomo Chemical Co., Ltd.","owner_display_name":"Sumitomo Pharma Co., Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15116277.0,"shares_display":"15,116,277","price_per_share":8.6,"price_display":"8.60","price_state":"stated","total_value":129999982.2,"total_display":"129,999,982.20","total_whole":"129,999,982","shares_owned_after":71251083.0,"shares_owned_after_display":"71,251,083","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-06-22","filed_date":"2023-06-26","scope":"insider"},{"id":8644394,"accession":"0000899243-23-007864","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-007864","line_url":"/filing/0000899243-23-007864#line-1","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitomo Pharma Co., Ltd.; Sumitomo Chemical Co., Ltd.; Sumitovant Biopharma Ltd.","owner_display_name":"Sumitomo Pharma Co., Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":51599200.0,"shares_display":"51,599,200","price_per_share":27.0,"price_display":"27.00","price_state":"stated","total_value":1393178400.0,"total_display":"1,393,178,400.00","total_whole":"1,393,178,400","shares_owned_after":45798176.0,"shares_owned_after_display":"45,798,176","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-03-10","filed_date":"2023-03-10","scope":"insider"},{"id":5087961,"accession":"0000899243-21-038387","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-038387","line_url":"/filing/0000899243-21-038387#line-1","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Dainippon Sumitomo Pharma Co Ltd; Sumitovant Biopharma Ltd.; Sumitomo Chemical Co., Ltd.","owner_display_name":"Dainippon Sumitomo Pharma Co Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20677.0,"shares_display":"20,677","price_per_share":22.8458,"price_display":"22.85","price_state":"stated","total_value":472382.6066,"total_display":"472,382.61","total_whole":"472,383","shares_owned_after":50041181.0,"shares_owned_after_display":"50,041,181","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-28","filed_date":"2021-09-30","scope":"insider"},{"id":4929889,"accession":"0000899243-21-038083","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-21-038083","line_url":"/filing/0000899243-21-038083","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Dainippon Sumitomo Pharma Co Ltd; Sumitomo Chemical Co., Ltd.; Sumitovant Biopharma Ltd.","owner_display_name":"Dainippon Sumitomo Pharma Co Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":48000.0,"shares_display":"48,000","price_per_share":24.21645495,"price_display":"24.22","price_state":"stated","total_value":1162389.8376,"total_display":"1,162,389.84","total_whole":"1,162,390","shares_owned_after":50018272.0,"shares_owned_after_display":"50,018,272","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-27","filed_date":"2021-09-28","scope":"insider","n_lines":2},{"id":4929882,"accession":"0000899243-21-038083","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-038083","line_url":"/filing/0000899243-21-038083#line-1","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Dainippon Sumitomo Pharma Co Ltd; Sumitomo Chemical Co., Ltd.; Sumitovant Biopharma Ltd.","owner_display_name":"Dainippon Sumitomo Pharma Co Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":36000.0,"shares_display":"36,000","price_per_share":23.4041,"price_display":"23.40","price_state":"stated","total_value":842547.6,"total_display":"842,547.60","total_whole":"842,548","shares_owned_after":49972504.0,"shares_owned_after_display":"49,972,504","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-24","filed_date":"2021-09-28","scope":"insider"},{"id":4267541,"accession":"0000899243-21-037631","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-21-037631","line_url":"/filing/0000899243-21-037631","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Dainippon Sumitomo Pharma Co Ltd; Sumitomo Chemical Co., Ltd.; Sumitovant Biopharma Ltd.","owner_display_name":"Dainippon Sumitomo Pharma Co Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":54778.0,"shares_display":"54,778","price_per_share":23.060637270437038,"price_display":"23.06","price_state":"stated","total_value":1263215.5884,"total_display":"1,263,215.59","total_whole":"1,263,216","shares_owned_after":49931193.0,"shares_owned_after_display":"49,931,193","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-23","filed_date":"2021-09-24","scope":"insider","n_lines":2},{"id":4267528,"accession":"0000899243-21-037631","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-037631","line_url":"/filing/0000899243-21-037631#line-1","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Dainippon Sumitomo Pharma Co Ltd; Sumitomo Chemical Co., Ltd.; Sumitovant Biopharma Ltd.","owner_display_name":"Dainippon Sumitomo Pharma Co Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":84018.0,"shares_display":"84,018","price_per_share":21.9597,"price_display":"21.96","price_state":"stated","total_value":1845010.0746,"total_display":"1,845,010.07","total_whole":"1,845,010","shares_owned_after":49881726.0,"shares_owned_after_display":"49,881,726","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-22","filed_date":"2021-09-24","scope":"insider"},{"id":4975288,"accession":"0000899243-21-037114","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-037114","line_url":"/filing/0000899243-21-037114#line-2","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Dainippon Sumitomo Pharma Co Ltd; Sumitovant Biopharma Ltd.; Sumitomo Chemical Co., Ltd.","owner_display_name":"Dainippon Sumitomo Pharma Co Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":43000.0,"shares_display":"43,000","price_per_share":22.4756,"price_display":"22.48","price_state":"stated","total_value":966450.8,"total_display":"966,450.80","total_whole":"966,451","shares_owned_after":49797708.0,"shares_owned_after_display":"49,797,708","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-21","filed_date":"2021-09-22","scope":"insider"},{"id":4975284,"accession":"0000899243-21-037114","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-037114","line_url":"/filing/0000899243-21-037114#line-1","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Dainippon Sumitomo Pharma Co Ltd; Sumitovant Biopharma Ltd.; Sumitomo Chemical Co., Ltd.","owner_display_name":"Dainippon Sumitomo Pharma Co Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":38273.0,"shares_display":"38,273","price_per_share":22.0957,"price_display":"22.10","price_state":"stated","total_value":845668.7261,"total_display":"845,668.73","total_whole":"845,669","shares_owned_after":49754708.0,"shares_owned_after_display":"49,754,708","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-20","filed_date":"2021-09-22","scope":"insider"},{"id":5038406,"accession":"0000899243-21-036597","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-036597","line_url":"/filing/0000899243-21-036597#line-2","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Dainippon Sumitomo Pharma Co Ltd; Sumitomo Chemical Co., Ltd.; Sumitovant Biopharma Ltd.","owner_display_name":"Dainippon Sumitomo Pharma Co Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":37913.0,"shares_display":"37,913","price_per_share":22.7918,"price_display":"22.79","price_state":"stated","total_value":864105.5134,"total_display":"864,105.51","total_whole":"864,106","shares_owned_after":49716435.0,"shares_owned_after_display":"49,716,435","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-17","filed_date":"2021-09-20","scope":"insider"},{"id":5038397,"accession":"0000899243-21-036597","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-036597","line_url":"/filing/0000899243-21-036597#line-1","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Dainippon Sumitomo Pharma Co Ltd; Sumitomo Chemical Co., Ltd.; Sumitovant Biopharma Ltd.","owner_display_name":"Dainippon Sumitomo Pharma Co Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":21.751,"price_display":"21.75","price_state":"stated","total_value":1087550.0,"total_display":"1,087,550.00","total_whole":"1,087,550","shares_owned_after":49678522.0,"shares_owned_after_display":"49,678,522","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-16","filed_date":"2021-09-20","scope":"insider"},{"id":4760992,"accession":"0000899243-21-036290","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-21-036290","line_url":"/filing/0000899243-21-036290#line-3","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Dainippon Sumitomo Pharma Co Ltd; Sumitovant Biopharma Ltd.; Sumitomo Chemical Co., Ltd.","owner_display_name":"Dainippon Sumitomo Pharma Co Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":89864.0,"shares_display":"89,864","price_per_share":21.9831,"price_display":"21.98","price_state":"stated","total_value":1975489.2984,"total_display":"1,975,489.30","total_whole":"1,975,489","shares_owned_after":49628522.0,"shares_owned_after_display":"49,628,522","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-15","filed_date":"2021-09-16","scope":"insider"},{"id":4760989,"accession":"0000899243-21-036290","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-036290","line_url":"/filing/0000899243-21-036290","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Dainippon Sumitomo Pharma Co Ltd; Sumitovant Biopharma Ltd.; Sumitomo Chemical Co., Ltd.","owner_display_name":"Dainippon Sumitomo Pharma Co Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":71300.0,"shares_display":"71,300","price_per_share":22.099378788218793,"price_display":"22.10","price_state":"stated","total_value":1575685.7076,"total_display":"1,575,685.71","total_whole":"1,575,686","shares_owned_after":49532486.0,"shares_owned_after_display":"49,532,486","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-14","filed_date":"2021-09-16","scope":"insider","n_lines":2},{"id":4929853,"accession":"0000899243-21-035821","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-21-035821","line_url":"/filing/0000899243-21-035821","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitovant Biopharma Ltd.; Sumitomo Chemical Co., Ltd.; Dainippon Sumitomo Pharma Co Ltd","owner_display_name":"Sumitovant Biopharma Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":83178.0,"shares_display":"83,178","price_per_share":23.384171350597512,"price_display":"23.38","price_state":"stated","total_value":1945048.6046,"total_display":"1,945,048.60","total_whole":"1,945,049","shares_owned_after":49437330.0,"shares_owned_after_display":"49,437,330","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-13","filed_date":"2021-09-14","scope":"insider","n_lines":2},{"id":4929847,"accession":"0000899243-21-035821","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-035821","line_url":"/filing/0000899243-21-035821#line-1","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitovant Biopharma Ltd.; Sumitomo Chemical Co., Ltd.; Dainippon Sumitomo Pharma Co Ltd","owner_display_name":"Sumitovant Biopharma Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":30000.0,"shares_display":"30,000","price_per_share":25.113,"price_display":"25.11","price_state":"stated","total_value":753390.0,"total_display":"753,390.00","total_whole":"753,390","shares_owned_after":49384180.0,"shares_owned_after_display":"49,384,180","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-10","filed_date":"2021-09-14","scope":"insider"},{"id":5194538,"accession":"0000899243-21-035564","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-035564","line_url":"/filing/0000899243-21-035564#line-2","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Dainippon Sumitomo Pharma Co Ltd; Sumitomo Chemical Co., Ltd.; Sumitovant Biopharma Ltd.","owner_display_name":"Dainippon Sumitomo Pharma Co Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":37000.0,"shares_display":"37,000","price_per_share":25.5175,"price_display":"25.52","price_state":"stated","total_value":944147.5,"total_display":"944,147.50","total_whole":"944,148","shares_owned_after":49354180.0,"shares_owned_after_display":"49,354,180","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-09","filed_date":"2021-09-10","scope":"insider"},{"id":5194533,"accession":"0000899243-21-035564","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-035564","line_url":"/filing/0000899243-21-035564#line-1","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Dainippon Sumitomo Pharma Co Ltd; Sumitomo Chemical Co., Ltd.; Sumitovant Biopharma Ltd.","owner_display_name":"Dainippon Sumitomo Pharma Co Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":21902.0,"shares_display":"21,902","price_per_share":25.7357,"price_display":"25.74","price_state":"stated","total_value":563663.3014,"total_display":"563,663.30","total_whole":"563,663","shares_owned_after":49317180.0,"shares_owned_after_display":"49,317,180","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-08","filed_date":"2021-09-10","scope":"insider"},{"id":5525901,"accession":"0000899243-21-035342","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-21-035342","line_url":"/filing/0000899243-21-035342","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitovant Biopharma Ltd.; Dainippon Sumitomo Pharma Co Ltd; Sumitomo Chemical Co., Ltd.","owner_display_name":"Sumitovant Biopharma Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":33200.0,"shares_display":"33,200","price_per_share":26.232804343373495,"price_display":"26.23","price_state":"stated","total_value":870929.1042,"total_display":"870,929.10","total_whole":"870,929","shares_owned_after":49290365.0,"shares_owned_after_display":"49,290,365","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-07","filed_date":"2021-09-08","scope":"insider","n_lines":2},{"id":5525895,"accession":"0000899243-21-035342","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-035342","line_url":"/filing/0000899243-21-035342","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitovant Biopharma Ltd.; Dainippon Sumitomo Pharma Co Ltd; Sumitomo Chemical Co., Ltd.","owner_display_name":"Sumitovant Biopharma Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":31200.0,"shares_display":"31,200","price_per_share":26.7626125,"price_display":"26.76","price_state":"stated","total_value":834993.51,"total_display":"834,993.51","total_whole":"834,994","shares_owned_after":49260700.0,"shares_owned_after_display":"49,260,700","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-03","filed_date":"2021-09-08","scope":"insider","n_lines":2},{"id":4267336,"accession":"0000899243-21-035135","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-21-035135","line_url":"/filing/0000899243-21-035135","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitomo Chemical Co., Ltd.; Sumitovant Biopharma Ltd.; Dainippon Sumitomo Pharma Co Ltd","owner_display_name":"Sumitomo Chemical Co., Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":63102.0,"shares_display":"63,102","price_per_share":26.083050621216444,"price_display":"26.08","price_state":"stated","total_value":1645892.6603,"total_display":"1,645,892.66","total_whole":"1,645,893","shares_owned_after":49225030.0,"shares_owned_after_display":"49,225,030","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-02","filed_date":"2021-09-03","scope":"insider","n_lines":3},{"id":4267315,"accession":"0000899243-21-035135","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-035135","line_url":"/filing/0000899243-21-035135#line-1","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitomo Chemical Co., Ltd.; Sumitovant Biopharma Ltd.; Dainippon Sumitomo Pharma Co Ltd","owner_display_name":"Sumitomo Chemical Co., Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":40000.0,"shares_display":"40,000","price_per_share":24.8257,"price_display":"24.83","price_state":"stated","total_value":993028.0,"total_display":"993,028.00","total_whole":"993,028","shares_owned_after":49167776.0,"shares_owned_after_display":"49,167,776","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-09-01","filed_date":"2021-09-03","scope":"insider"},{"id":5431799,"accession":"0000899243-21-034765","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-034765","line_url":"/filing/0000899243-21-034765#line-2","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitovant Biopharma Ltd.; Dainippon Sumitomo Pharma Co Ltd; Sumitomo Chemical Co., Ltd.","owner_display_name":"Sumitovant Biopharma Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":39000.0,"shares_display":"39,000","price_per_share":24.2791,"price_display":"24.28","price_state":"stated","total_value":946884.9,"total_display":"946,884.90","total_whole":"946,885","shares_owned_after":49127776.0,"shares_owned_after_display":"49,127,776","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-31","filed_date":"2021-09-01","scope":"insider"},{"id":5431794,"accession":"0000899243-21-034765","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-034765","line_url":"/filing/0000899243-21-034765#line-1","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitovant Biopharma Ltd.; Dainippon Sumitomo Pharma Co Ltd; Sumitomo Chemical Co., Ltd.","owner_display_name":"Sumitovant Biopharma Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":70000.0,"shares_display":"70,000","price_per_share":23.9157,"price_display":"23.92","price_state":"stated","total_value":1674099.0,"total_display":"1,674,099.00","total_whole":"1,674,099","shares_owned_after":49088776.0,"shares_owned_after_display":"49,088,776","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-30","filed_date":"2021-09-01","scope":"insider"},{"id":4975155,"accession":"0000899243-21-034525","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-034525","line_url":"/filing/0000899243-21-034525#line-2","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitovant Biopharma Ltd.; Dainippon Sumitomo Pharma Co Ltd; Sumitomo Chemical Co., Ltd.","owner_display_name":"Sumitovant Biopharma Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":37038.0,"shares_display":"37,038","price_per_share":23.1722,"price_display":"23.17","price_state":"stated","total_value":858251.9436,"total_display":"858,251.94","total_whole":"858,252","shares_owned_after":49018776.0,"shares_owned_after_display":"49,018,776","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-27","filed_date":"2021-08-30","scope":"insider"},{"id":4975149,"accession":"0000899243-21-034525","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-034525","line_url":"/filing/0000899243-21-034525#line-1","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitovant Biopharma Ltd.; Dainippon Sumitomo Pharma Co Ltd; Sumitomo Chemical Co., Ltd.","owner_display_name":"Sumitovant Biopharma Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":40000.0,"shares_display":"40,000","price_per_share":22.6728,"price_display":"22.67","price_state":"stated","total_value":906912.0,"total_display":"906,912.00","total_whole":"906,912","shares_owned_after":48981738.0,"shares_owned_after_display":"48,981,738","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-26","filed_date":"2021-08-30","scope":"insider"},{"id":5276685,"accession":"0000899243-21-034281","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-034281","line_url":"/filing/0000899243-21-034281#line-2","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Dainippon Sumitomo Pharma Co Ltd; Sumitovant Biopharma Ltd.; Sumitomo Chemical Co., Ltd.","owner_display_name":"Dainippon Sumitomo Pharma Co Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":28709.0,"shares_display":"28,709","price_per_share":22.4375,"price_display":"22.44","price_state":"stated","total_value":644158.1875,"total_display":"644,158.19","total_whole":"644,158","shares_owned_after":48941738.0,"shares_owned_after_display":"48,941,738","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-25","filed_date":"2021-08-26","scope":"insider"},{"id":5276682,"accession":"0000899243-21-034281","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-034281","line_url":"/filing/0000899243-21-034281#line-1","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Dainippon Sumitomo Pharma Co Ltd; Sumitovant Biopharma Ltd.; Sumitomo Chemical Co., Ltd.","owner_display_name":"Dainippon Sumitomo Pharma Co Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":34299.0,"shares_display":"34,299","price_per_share":22.37,"price_display":"22.37","price_state":"stated","total_value":767268.63,"total_display":"767,268.63","total_whole":"767,269","shares_owned_after":48913029.0,"shares_owned_after_display":"48,913,029","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-24","filed_date":"2021-08-26","scope":"insider"},{"id":4306320,"accession":"0000899243-21-034046","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-21-034046","line_url":"/filing/0000899243-21-034046","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitomo Chemical Co., Ltd.; Dainippon Sumitomo Pharma Co Ltd; Sumitovant Biopharma Ltd.","owner_display_name":"Sumitomo Chemical Co., Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":55447.0,"shares_display":"55,447","price_per_share":22.304832465237073,"price_display":"22.30","price_state":"stated","total_value":1236736.0457,"total_display":"1,236,736.05","total_whole":"1,236,736","shares_owned_after":48878730.0,"shares_owned_after_display":"48,878,730","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-23","filed_date":"2021-08-24","scope":"insider","n_lines":2},{"id":4306311,"accession":"0000899243-21-034046","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-034046","line_url":"/filing/0000899243-21-034046#line-1","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitomo Chemical Co., Ltd.; Dainippon Sumitomo Pharma Co Ltd; Sumitovant Biopharma Ltd.","owner_display_name":"Sumitomo Chemical Co., Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":46478.0,"shares_display":"46,478","price_per_share":20.8602,"price_display":"20.86","price_state":"stated","total_value":969540.3756,"total_display":"969,540.38","total_whole":"969,540","shares_owned_after":48823283.0,"shares_owned_after_display":"48,823,283","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-20","filed_date":"2021-08-24","scope":"insider"},{"id":5237744,"accession":"0000899243-21-033840","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-033840","line_url":"/filing/0000899243-21-033840#line-2","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitomo Chemical Co., Ltd.; Sumitovant Biopharma Ltd.; Dainippon Sumitomo Pharma Co Ltd","owner_display_name":"Sumitomo Chemical Co., Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":46792.0,"shares_display":"46,792","price_per_share":21.5084,"price_display":"21.51","price_state":"stated","total_value":1006421.0528,"total_display":"1,006,421.05","total_whole":"1,006,421","shares_owned_after":48776805.0,"shares_owned_after_display":"48,776,805","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-19","filed_date":"2021-08-20","scope":"insider"},{"id":5237739,"accession":"0000899243-21-033840","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-033840","line_url":"/filing/0000899243-21-033840#line-1","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitomo Chemical Co., Ltd.; Sumitovant Biopharma Ltd.; Dainippon Sumitomo Pharma Co Ltd","owner_display_name":"Sumitomo Chemical Co., Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":17116.0,"shares_display":"17,116","price_per_share":21.4473,"price_display":"21.45","price_state":"stated","total_value":367091.9868,"total_display":"367,091.99","total_whole":"367,092","shares_owned_after":48730013.0,"shares_owned_after_display":"48,730,013","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-18","filed_date":"2021-08-20","scope":"insider"},{"id":5132788,"accession":"0000899243-21-033476","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-21-033476","line_url":"/filing/0000899243-21-033476#line-3","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitomo Chemical Co., Ltd.; Sumitovant Biopharma Ltd.; Dainippon Sumitomo Pharma Co Ltd","owner_display_name":"Sumitomo Chemical Co., Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":23549.0,"shares_display":"23,549","price_per_share":20.8947,"price_display":"20.89","price_state":"stated","total_value":492049.2903,"total_display":"492,049.29","total_whole":"492,049","shares_owned_after":48712897.0,"shares_owned_after_display":"48,712,897","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-17","filed_date":"2021-08-18","scope":"insider"},{"id":5132783,"accession":"0000899243-21-033476","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-033476","line_url":"/filing/0000899243-21-033476","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitomo Chemical Co., Ltd.; Sumitovant Biopharma Ltd.; Dainippon Sumitomo Pharma Co Ltd","owner_display_name":"Sumitomo Chemical Co., Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":48167.0,"shares_display":"48,167","price_per_share":21.36618274337202,"price_display":"21.37","price_state":"stated","total_value":1029144.9242,"total_display":"1,029,144.92","total_whole":"1,029,145","shares_owned_after":48683966.0,"shares_owned_after_display":"48,683,966","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-16","filed_date":"2021-08-18","scope":"insider","n_lines":2},{"id":2039831,"accession":"0000899243-20-013825","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-013825","line_url":"/filing/0000899243-20-013825#line-2","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitovant Biopharma Ltd.; Sumitomo Chemical Co., Ltd.; Dainippon Sumitomo Pharma Co Ltd","owner_display_name":"Sumitovant Biopharma Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":37897.0,"shares_display":"37,897","price_per_share":12.5831,"price_display":"12.58","price_state":"stated","total_value":476861.7407,"total_display":"476,861.74","total_whole":"476,862","shares_owned_after":48641181.0,"shares_owned_after_display":"48,641,181","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-05-20","filed_date":"2020-05-21","scope":"insider"},{"id":2039829,"accession":"0000899243-20-013825","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-20-013825","line_url":"/filing/0000899243-20-013825#line-1","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitovant Biopharma Ltd.; Sumitomo Chemical Co., Ltd.; Dainippon Sumitomo Pharma Co Ltd","owner_display_name":"Sumitovant Biopharma Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":12.101,"price_display":"12.10","price_state":"stated","total_value":605050.0,"total_display":"605,050.00","total_whole":"605,050","shares_owned_after":48603284.0,"shares_owned_after_display":"48,603,284","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-05-19","filed_date":"2020-05-21","scope":"insider"},{"id":2506868,"accession":"0000899243-20-013546","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-013546","line_url":"/filing/0000899243-20-013546#line-2","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitomo Chemical Co., Ltd.; Sumitovant Biopharma Ltd.; Dainippon Sumitomo Pharma Co Ltd","owner_display_name":"Sumitomo Chemical Co., Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":35000.0,"shares_display":"35,000","price_per_share":12.3607,"price_display":"12.36","price_state":"stated","total_value":432624.5,"total_display":"432,624.50","total_whole":"432,625","shares_owned_after":48553284.0,"shares_owned_after_display":"48,553,284","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-05-18","filed_date":"2020-05-19","scope":"insider"},{"id":2506861,"accession":"0000899243-20-013546","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-20-013546","line_url":"/filing/0000899243-20-013546#line-1","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitomo Chemical Co., Ltd.; Sumitovant Biopharma Ltd.; Dainippon Sumitomo Pharma Co Ltd","owner_display_name":"Sumitomo Chemical Co., Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":49812.0,"shares_display":"49,812","price_per_share":12.1249,"price_display":"12.12","price_state":"stated","total_value":603965.5188,"total_display":"603,965.52","total_whole":"603,966","shares_owned_after":48518284.0,"shares_owned_after_display":"48,518,284","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-05-15","filed_date":"2020-05-19","scope":"insider"},{"id":2132712,"accession":"0000899243-20-013205","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-013205","line_url":"/filing/0000899243-20-013205#line-2","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitovant Biopharma Ltd.; Sumitomo Chemical Co., Ltd.; Dainippon Sumitomo Pharma Co Ltd","owner_display_name":"Sumitovant Biopharma Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":12.0152,"price_display":"12.02","price_state":"stated","total_value":600760.0,"total_display":"600,760.00","total_whole":"600,760","shares_owned_after":48468472.0,"shares_owned_after_display":"48,468,472","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-05-14","filed_date":"2020-05-15","scope":"insider"},{"id":2132709,"accession":"0000899243-20-013205","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-20-013205","line_url":"/filing/0000899243-20-013205#line-1","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Sumitovant Biopharma Ltd.; Sumitomo Chemical Co., Ltd.; Dainippon Sumitomo Pharma Co Ltd","owner_display_name":"Sumitovant Biopharma Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":41331.0,"shares_display":"41,331","price_per_share":12.3791,"price_display":"12.38","price_state":"stated","total_value":511640.5821,"total_display":"511,640.58","total_whole":"511,641","shares_owned_after":48418472.0,"shares_owned_after_display":"48,418,472","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-05-13","filed_date":"2020-05-15","scope":"insider"},{"id":3032841,"accession":"0000899243-20-013027","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-013027","line_url":"/filing/0000899243-20-013027#line-2","is_derivative":false,"issuer_cik":"0001446601","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001446601","owner_cik":null,"owner_name":"Dainippon Sumitomo Pharma Co Ltd; Sumitomo Chemical Co., Ltd.; Sumitovant Biopharma Ltd.","owner_display_name":"Dainippon Sumitomo Pharma Co Ltd","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":24448.0,"shares_display":"24,448","price_per_share":13.5146,"price_display":"13.51","price_state":"stated","total_value":330404.9408,"total_display":"330,404.94","total_whole":"330,405","shares_owned_after":48377141.0,"shares_owned_after_display":"48,377,141","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-05-12","filed_date":"2020-05-13","scope":"insider"}],"collapsed":true,"next_cursor":"2020-05-12|3032841","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001635088","name":"Roivant Sciences Ltd.","url":"/issuer/0001635088","role":"Ten percent owner","n_filings":1,"first_seen":"2023-06-26","last_seen":"2023-06-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001679082","name":"Myovant Sciences Ltd.","url":"/issuer/0001679082","role":"Ten percent owner","n_filings":42,"first_seen":"2020-03-18","last_seen":"2023-03-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001740547","name":"Urovant Sciences Ltd.","url":"/issuer/0001740547","role":"Other","n_filings":1,"first_seen":"2020-02-21","last_seen":"2020-02-21"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001798550","retrieved_at":"2026-08-22T16:06:54+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}